Glucuronoxylomannan in theCryptococcusspecies capsule as a target for CAR+T-cell therapy
Abstract The genusCryptococcuscomprises two major fungal species that cause clinical infections in humans:C. gattiiandC. neoformans. To establish invasive human disease, inhaled Cryptococci must penetrate the lung tissue and reproduce. Each year, about 1 million cases ofCryptococcusinfection are reported worldwide, and the infection’s mortality rate ranges from 20% to 70%. HIV+/AIDS patients are highly susceptible toCryptococcusinfection. Therefore, we hypothesized that CD8+T cells could be redirected to target glucuronoxylomannan (GXM), a sugar present in theCryptococcusspecies capsule, via expression of a GXM-specific chimeric antigen receptor (GXMR-CAR) for treatment of cryptococcosis. GXMR-CAR has an anti-GXM single-chain variable fragment followed by an IgG4 stalk, a CD28 transmembrane domain, and CD3-ς and CD28 signaling domains. After lentiviral transduction of human T cells with the GXMR-CAR construct, flow cytometry demonstrated that 82.4% of the cells expressed GXMR-CAR on their surface. To determine whether the GXMR-CAR+T cells exhibited GXM-specific recognition, these cells were incubated with GXM for 24 h and examined using bright-field microscopy. Large clusters of proliferating GXMR-CAR+T cells were observed, while no clusters were present in the control cells. Moreover, the interaction of GXM with GXMR-CAR+T cells was detected via flow cytometry using a GXM-specific antibody. The ability of GXMR-CAR T cells to bind to the yeast form ofC. neoformanswas detected by fluorescent microscopy, but no binding was detected with NoDNA T cells. Furthermore, when GXMR-CAR+T cells were administered to immunocompromised NSG mice infected withC. neoformanstheirC. neoformansburden was significantly lower than mock-transduced control T cell treated mice as shown via immunofluorescence using an anti-GXM antibody and Gomori methenamine-silver (GMS) staining of Titan cells in lung tissue. Thus, these findings demonstrated the effectiveness of GXMR-CAR+T-cell therapy for cryptococcosis in a murine model.Author summary Cryptococcus gattiiinfects both immunocompetent and immunodeficient patients such as those with HIV/AIDS, whileC. neoformansusually infects only immunocompromised patients. Every year, almost one million HIV/AIDS patients suffer fromCryptococcusfungal co-infection. At present, no curative treatment is available to treat cryptococcosis in chronic HIV/AIDS patients. The objective of this research was to develop novel “Bioengineered”Cryptococcusspecific chimeric antigen receptor (CAR) CD8+T-cells to target and killCryptococcus. By using a culture model, we demonstrated that theCryptococcusspecific CAR T cells were able to bind to the yeast form ofC. neoformans.Using a mouse model ofCryptococcus, theCryptococcusspecific CAR treated group showed a significant reduction of fungal burden in lung tissue when compared to the control group. This gives new hope to HIV/AIDS patients suffering from cryptococcal infections..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
bioRxiv.org - (2021) vom: 15. Dez. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
da Silva, Thiago Aparecido [VerfasserIn] |
---|
Links: |
---|
doi: |
10.1101/715045 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI000577758 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI000577758 | ||
003 | DE-627 | ||
005 | 20230429100815.0 | ||
007 | cr uuu---uuuuu | ||
008 | 200312s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/715045 |2 doi | |
035 | |a (DE-627)XBI000577758 | ||
035 | |a (biorXiv)10.1101/715045 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a da Silva, Thiago Aparecido |e verfasserin |4 aut | |
245 | 1 | 0 | |a Glucuronoxylomannan in theCryptococcusspecies capsule as a target for CAR+T-cell therapy |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract The genusCryptococcuscomprises two major fungal species that cause clinical infections in humans:C. gattiiandC. neoformans. To establish invasive human disease, inhaled Cryptococci must penetrate the lung tissue and reproduce. Each year, about 1 million cases ofCryptococcusinfection are reported worldwide, and the infection’s mortality rate ranges from 20% to 70%. HIV+/AIDS patients are highly susceptible toCryptococcusinfection. Therefore, we hypothesized that CD8+T cells could be redirected to target glucuronoxylomannan (GXM), a sugar present in theCryptococcusspecies capsule, via expression of a GXM-specific chimeric antigen receptor (GXMR-CAR) for treatment of cryptococcosis. GXMR-CAR has an anti-GXM single-chain variable fragment followed by an IgG4 stalk, a CD28 transmembrane domain, and CD3-ς and CD28 signaling domains. After lentiviral transduction of human T cells with the GXMR-CAR construct, flow cytometry demonstrated that 82.4% of the cells expressed GXMR-CAR on their surface. To determine whether the GXMR-CAR+T cells exhibited GXM-specific recognition, these cells were incubated with GXM for 24 h and examined using bright-field microscopy. Large clusters of proliferating GXMR-CAR+T cells were observed, while no clusters were present in the control cells. Moreover, the interaction of GXM with GXMR-CAR+T cells was detected via flow cytometry using a GXM-specific antibody. The ability of GXMR-CAR T cells to bind to the yeast form ofC. neoformanswas detected by fluorescent microscopy, but no binding was detected with NoDNA T cells. Furthermore, when GXMR-CAR+T cells were administered to immunocompromised NSG mice infected withC. neoformanstheirC. neoformansburden was significantly lower than mock-transduced control T cell treated mice as shown via immunofluorescence using an anti-GXM antibody and Gomori methenamine-silver (GMS) staining of Titan cells in lung tissue. Thus, these findings demonstrated the effectiveness of GXMR-CAR+T-cell therapy for cryptococcosis in a murine model.Author summary Cryptococcus gattiiinfects both immunocompetent and immunodeficient patients such as those with HIV/AIDS, whileC. neoformansusually infects only immunocompromised patients. Every year, almost one million HIV/AIDS patients suffer fromCryptococcusfungal co-infection. At present, no curative treatment is available to treat cryptococcosis in chronic HIV/AIDS patients. The objective of this research was to develop novel “Bioengineered”Cryptococcusspecific chimeric antigen receptor (CAR) CD8+T-cells to target and killCryptococcus. By using a culture model, we demonstrated that theCryptococcusspecific CAR T cells were able to bind to the yeast form ofC. neoformans.Using a mouse model ofCryptococcus, theCryptococcusspecific CAR treated group showed a significant reduction of fungal burden in lung tissue when compared to the control group. This gives new hope to HIV/AIDS patients suffering from cryptococcal infections. | ||
700 | 1 | |a Hauser, Paul J. |e verfasserin |4 aut | |
700 | 1 | |a Bandey, Irfan |e verfasserin |4 aut | |
700 | 1 | |a Laskowski, Tamara |e verfasserin |4 aut | |
700 | 1 | |a Wang, Qi |e verfasserin |4 aut | |
700 | 1 | |a Najjar, Amer M. |e verfasserin |4 aut | |
700 | 1 | |a Kumaresan, Pappanaicken R. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Dez. |
773 | 1 | 8 | |g year:2021 |g day:15 |g month:12 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.jcyt.2020.11.002 |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/715045 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 15 |c 12 | ||
953 | |2 045F |a 570 |